Subjects and study design
renal and hepatic diseases, periodontitis, allergy
OVARIAN CANCER, PERIODONTITIS, DISEASE, ALLERGY, PEMPHIGUS, LEUKOPLAKIA
In this randomized, double-blind clinical trial, 40 periodontitis patients referring to the Periodontics Department of Dental School, Shahid Sadoughi University of Medical Sciences, Yazd, were selected. According to the principles of the Helsinki declaration, after examination and diagnosis of periodontal symptoms and considering inclusion and exclusion criteria, the necessary information was provided, and written consent was obtained. Then, the subjects were randomly assigned to two groups: case (n = 20) and control (n = 20). The patients were free to leave the study at any time they wished.The inclusion criteria consisted of an age range of 30–60 years and moderate to severe periodontitis. The exclusion criteria consisted of pregnancy, lactation, traveling for > 2 weeks, smoking, taking immunosuppressive medications, taking non-steroidal anti-inflammatory drugs, antihypertensive agents, antibiotics drugs, anti-coagulant drugs like warfarin, taking insulin, and patients treated for uterine, breast, and ovarian cancer, patients with advanced renal and hepatic diseases, those with an allergy to grapes, blackberry, or blueberry, history of periodontitis treatment in the past six months and patients with active oral disease like pemphigus, leukoplakia.This clinical trial was approved by the Ethics Committee of Shahid Sadoughi University of Medical Sciences under the code IR.SSU.REC.1396.206, and the IRCT Registration code was IRCT20171015036782N6.